Cormedix Inc. revenue
Cormedix Inc.'s revenue was $312m in fiscal 2025, up 617.0% on the year before. Since fiscal 2013 ($2,001) it has grown at a compound 196.5% a year. Over the last twelve months it was $462m.
Revenue history
| Fiscal year | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43 | 312 | 462 |
| Growth on the year before | — | — | +>999% | +11.0% | +6.7% | +47.0% | +30.5% | −34.1% | −15.5% | −20.2% | −65.7% | +>999% | +617.0% | — |
| Gross profit | 0 | −0 | −0 | −0 | −0 | 0 | 0 | −0 | 0 | 0 | 0 | 40 | 276 | 383 |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $304M | 97.6% | ▲ 600.1% |
| Defen Cath (part of Products) | $259M | 85.0% | ▲ 495.4% |
| Melinta Portfolio (part of Products) | $45.5M | 15.0% | — |
| Contract Revenue | $7.4M | 2.4% | — |
From Cormedix Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Cormedix Inc. | $462m | 280.5% | 1135.4% |
| Arcutis Biotherapeutics, Inc. | $464m | 76.1% | 241.4% |
| Krystal Biotech, Inc. | $470m | 26.0% | 280.1% |
| Ardelyx, Inc. | $451m | 16.8% | 75.9% |
| Adma Biologics, Inc. | $512m | 8.0% | 35.0% |
| Novavax Inc | $414m | -61.6% | -36.3% |
Compare with peers
- Arcutis Biotherapeutics, Inc. revenue
- Krystal Biotech, Inc. revenue
- Ardelyx, Inc. revenue
- Adma Biologics, Inc. revenue
- Novavax Inc revenue
Head to head: ARQT vs CRMDCRMD vs KRYSARDX vs CRMD
More: Biotechnology stocks compared, Health Care sector, rankings of US companies